Determination of Pronostics Factors for Advanced Thyroid Carcinoma (pT3 pT4 or M1 at Diagnosis)

Hospices Civils de Lyon643 enrolled

Overview

It is generally estimated that 5 % of patients with thyroid cancer will develop distant metastases, and most of them had an advanced stage of the disease at presentation. Thirty per cent of them are resistant to radio iodine therapy and are called "refractory". Their long term survival is estimated to be less than 10 %. The objective of this study is to identify the factors associated with poor outcome in a cohort of patients with advanced thyroid cancer followed during 5 years. Anaplastic and medullary thyroid carcinomas were excluded.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

643

Conditions

Thyroid Cancer

Interventions

follow up visitOTHER

At least 1 follow up visit per year will be done and an additional visit if needed.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Man or woman ≥ 18 years. * Thyroid cancer differentiated from follicular origins (papillary, vesicular or poorly differentiated carcinoma). * TNM classification: stage pT3 (≥2 cm), or pT4 or M1 at diagnosis. * Patient after post operative radioiodine therapy. Exclusion Criteria: * Patient who can not be followed during the protocol. * Patient who does not consent.

Locations (1)

Hospices Civils de Lyon-Centre de Médecine Nucléaire Groupement Hospitalier Est 59 boulevard Pinel

Bron, France

Outcomes

Primary Outcomes

Rate of Thyroid cancer evolving to refractory stage

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.